Top

07-08-2017 | Vasculitis | Review | Article

Vasculitis update: pathogenesis and biomarkers

Journal: Pediatric Nephrology

Authors: Paul Brogan, Despina Eleftheriou

Publisher: Springer Berlin Heidelberg

Abstract

Better understanding of the pathogenesis and treatment of primary systemic vasculitides (PSV) has led to the development of many potentially clinically relevant biomarkers. Genome-wide association studies have highlighted that MHC class II polymorphisms may influence the development of particular anti-neutrophil cytoplasmic antibody (ANCA) serotypes, but not the clinical phenotype of ANCA-associated vasculitis (AAV). Although ANCAs are overall poor biomarkers of disease activity, they may be useful for the prediction of flares of renal and/or pulmonary vasculitis. Moreover, patients with proteinase 3 (PR3)-AAV may respond better to rituximab than cyclophosphamide. Newer biomarkers of renal vasculitis in AAV include urinary soluble CD163, and may in the future reduce the requirement for renal biopsy. Better understanding of dysregulated neutrophil activation in AAV has led to the identification of novel biomarkers including circulating microparticles, and neutrophil extracellular traps (NETs), although their clinical utility has not yet been realised. Studies examining endothelial injury and repair responses have additionally revealed indices that may have utility as disease activity and/or prognostic biomarkers. Last, next-generation sequencing technologies are revealing monogenic forms of vasculitis, such as deficiency of adenosine deaminase type 2 (DADA2), and are profoundly influencing the approach to the diagnosis and treatment of vasculitis in the young.

Eleftheriou D, Brogan PA (2016) Therapeutic advances in the treatment of vasculitis. Pediatr Rheumatol 14:26CrossRef

Ntatsaki E, Carruthers D, Chakravarty K, D’Cruz D, Harper L, Jayne D, Luqmani R, Mills J, Mooney J, Venning M, Watts RA (2014) BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford) 53:2306–2309CrossRef

Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalcindag N, Jayne DR, Mukhtyar C (2016) EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583–1594PubMedCrossRef

Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95CrossRef

Eleftheriou D, Batu ED, Ozen S, Brogan PA (2015) Vasculitis in children. Nephrol Dial Transplant 30 [Suppl 1]:i94–i103PubMed

Eleftheriou D, Gale H, Pilkington C, Fenton M, Sebire NJ, Brogan PA (2016) Eosinophilic granulomatosis with polyangiitis in childhood: retrospective experience from a tertiary referral centre in the UK. Rheumatology (Oxford) 55:1263–1272CrossRef

Brogan P, Eleftheriou D, Dillon M (2010) Small vessel vasculitis. Pediatr Nephrol 25:1025–1035PubMedCrossRef

Belostotsky VM, Shah V, Dillon MJ (2002) Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr Nephrol 17:754–761PubMedCrossRef

Akikusa JD, Schneider R, Harvey EA, Hebert D, Thorner PS, Laxer RM, Silverman ED (2007) Clinical features and outcome of pediatric Wegener’s granulomatosis. Arthritis Rheum 57:837–844PubMedCrossRef

10.

Cabral DA, Uribe AG, Benseler S, O’Neil KM, Hashkes PJ, Higgins G, Zeft AS, Lovell DJ, Kingsbury DJ, Stevens A (2009) Classification, presentation, and initial treatment of Wegener’s granulomatosis in childhood. Arthritis Rheum 60:3413–3424PubMedCrossRef

11.

Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221–232PubMedPubMedCentralCrossRef

12.

Hilhorst M, Wilde B, van Paassen P, Winkens B, van Breda VP, Tervaert JWC (2013) Improved outcome in anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis: a 30-year follow-up study. Nephrol Dial Transplant 28:373–379PubMedCrossRef

13.

Bohm M, Fernandez MIG, Ozen S, Pistorio A, Dolezalova P, Brogan P, Barbano G, Sengler C, Klein-Gitelman M, Quartier P (2014) Clinical features of childhood granulomatosis with polyangiitis (Wegener’s granulomatosis). Pediatr Rheumatol 12:1–5CrossRef

14.

Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, Amouroux J, Casassus P, Jarrousse B (1999) Microscopic polyangiitis. Arthritis Rheum 42:421–430PubMedCrossRef

15.

Pendergraft WF III, Nachman PH (2015) Recent pathogenetic advances in ANCA-associated vasculitis. Presse Med 44:e223–e229PubMedCrossRef

16.

Bansal PJ, Tobin MC (2004) Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 93:398–401PubMedCrossRef

17.

Schlieben DJ, Korbet SM, Kimura RE, Schwartz MM, Lewis EJ (2005) Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis 45:758–761PubMedCrossRef

18.

Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC (2002) Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110:955–963PubMedPubMedCentralCrossRef

19.

Little MA, Al-Ani B, Ren S, Al-Nuaimi H, Leite M Jr, Alpers CE, Savage CO, Duffield JS (2012) Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS One 7, e28626PubMedPubMedCentralCrossRef

20.

Jennette JC, Xiao H, Falk RJ (2006) Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 17:1235–1242PubMedCrossRef

21.

Morgan MD, Harper L, Williams J, Savage C (2006) Anti-neutrophil cytoplasm-associated glomerulonephritis. J Am Soc Nephrol 17:1224–1234PubMedCrossRef

22.

Hong Y, Eleftheriou D, Hussain AA, Price-Kuehne FE, Savage CO, Jayne D, Little MA, Salama AD, Klein NJ, Brogan PA (2012) Anti-neutrophil cytoplasmic antibodies stimulate release of neutrophil microparticles. J Am Soc Nephrol 23:49–62PubMedCrossRef

23.

Mulder AH, Stegeman CA, Kallenberg CG (1995) Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener’s granulomatosis: a predominant role for the IgG3 subclass of ANCA. Clin Exp Immunol 101:227–232PubMedPubMedCentralCrossRef

24.

Brogan PA (2007) What’s new in the aetiopathogenesis of vasculitis? Pediatr Nephrol 22:1083–1094PubMedCrossRef

25.

Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, Baslund B, Brenchley P, Bruchfeld A, Chaudhry AN, Cohen Tervaert JW, Deloukas P, Feighery C, Gross WL, Guillevin L, Gunnarsson I, Harper L, Hruskova Z, Little MA, Martorana D, Neumann T, Ohlsson S, Padmanabhan S, Pusey CD, Salama AD, Sanders JS, Savage CO, Segelmark M, Stegeman CA, Tesar V, Vaglio A, Wieczorek S, Wilde B, Zwerina J, Rees AJ, Clayton DG, Smith KG (2012) Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 367:214–223PubMedPubMedCentralCrossRef

26.

Carr EJ, Niederer HA, Williams J, Harper L, Watts RA, Lyons PA, Smith KG (2009) Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis. BMC Med Genet 10:121PubMedPubMedCentralCrossRef

27.

McKinney EF, Lyons PA, Carr EJ, Hollis JL, Jayne DR, Willcocks LC, Koukoulaki M, Brazma A, Jovanovic V, Kemeny DM, Pollard AJ, Macary PA, Chaudhry AN, Smith KG (2010) A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med 16:586–591, 1p following 591PubMedPubMedCentralCrossRef

28.

McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG (2015) T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523:612–616PubMedPubMedCentralCrossRef

29.

Arulkumaran N, Jawad S, Smith SW, Harper L, Brogan P, Pusey CD, Salama AD (2011) Long- term outcome of paediatric patients with ANCA vasculitis. Pediatr Rheumatol 9:12CrossRef

30.

Iglesias E, Eleftheriou D, Mankad K, Prabhakar P, Brogan PA (2014) Microscopic polyangiitis presenting with hemorrhagic stroke. J Child Neurol 29:NP1–NP4PubMedCrossRef

31.

Jayne D, Rasmussen N (2015) Twenty-five years of European Union collaboration in ANCA-associated vasculitis research. Nephrol Dial Transplant 30 [Suppl 1]:i1–i7PubMedCrossRef

32.

Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, Buoncompagni A, Lazar C, Bilge I, Uziel Y, Rigante D, Cantarini L, Hilario MO, Silva CA, Alegria M, Norambuena X, Belot A, Berkun Y, Estrella AI, Olivieri AN, Alpigiani MG, Rumba I, Sztajnbok F, Tambic-Bukovac L, Breda L, al-Mayouf S, Mihaylova D, Chasnyk V, Sengler C, Klein-Gitelman M, Djeddi D, Nuno L, Pruunsild C, Brunner J, Kondi A, Pagava K, Pederzoli S, Martini A, Ruperto N (2010) EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. II. Final classification criteria. Ann Rheum Dis 69:798–806PubMedCrossRef

33.

Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11PubMedCrossRef

34.

Koh JH, Kemna MJ, Cohen Tervaert JW, Kim WU (2016) Editorial: Can an increase in antineutrophil cytoplasmic autoantibody titer predict relapses in antineutrophil cytoplasmic antibody-associated vasculitis? Arthritis Rheumatol 68:1571–1573

35.

Davies DJ, Moran JE, Niall JF, Ryan GB (1982) Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed) 285:606CrossRef

36.

Finkielman JD, Merkel PA, Schroeder D, Hoffman GS, Spiera R, St Clair EW, Davis JC Jr, McCune WJ, Lears AK, Ytterberg SR, Hummel AM, Viss MA, Peikert T, Stone JH, Specks U (2007) Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 147:611–619PubMedCrossRef

37.

Kemna MJ, Damoiseaux J, Austen J, Winkens B, Peters J, van Paassen P, Cohen Tervaert JW (2015) ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol 26:537–542PubMedCrossRef

38.

Fussner LA, Hummel AM, Schroeder DR, Silva F, Cartin-Ceba R, Snyder MR, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, William St CE, Tchao NK, Stone JH, Specks U (2016) Factors determining the clinical utility of serial measurements of antineutrophil cytoplasmic antibodies targeting proteinase 3. Arthritis Rheumatol 68:1700–1710PubMedCrossRef

39.

Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CM, St Clair EW, Ikle D, Tchao NK, Ding L, Brunetta P, Choi HK, Monach PA, Fervenza F, Stone JH, Specks U (2016) Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis 75:1166–1169PubMedCrossRef

40.

Kessenbrock K, Krumbholz M, Schonermarck U, Back W, Gross WL, Werb Z, Grone HJ, Brinkmann V, Jenne DE (2009) Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 15:623–625PubMedPubMedCentralCrossRef

41.

Barnado A, Crofford LJ, Oates JC (2016) At the bedside: neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases. J Leukoc Biol 99:265–278PubMedCrossRef

42.

Wang H, Sha LL, Ma TT, Zhang LX, Chen M, Zhao MH (2016) Circulating level of neutrophil extracellular traps is not a useful biomarker for assessing disease activity in antineutrophil cytoplasmic antibody-associated vasculitis. PLoS One 11, e0148197PubMedPubMedCentralCrossRef

43.

Free ME, Falk RJ (2016) The search for a biomarker of relapse in ANCA-associated vasculitis. J Am Soc Nephrol 27:2551–2553PubMedPubMedCentral

44.

Tam FW, Sanders JS, George A, Hammad T, Miller C, Dougan T, Cook HT, Kallenberg CG, Gaskin G, Levy JB, Pusey CD (2004) Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol Dial Transplant 19:2761–2768PubMedCrossRef

45.

O’Reilly VP, Wong L, Kennedy C, Elliot LA, O’Meachair S, Coughlan AM, O’Brien EC, Ryan MM, Sandoval D, Connolly E, Dekkema GJ, Lau J, Abdulahad WH, Sanders JS, Heeringa P, Buckley C, O’Brien C, Finn S, Cohen CD, Lindemeyer MT, Hickey FB, O’Hara PV, Feighery C, Moran SM, Mellotte G, Clarkson MR, Dorman AJ, Murray PT, Little MA (2016) Urinary soluble CD163 in active renal vasculitis. J Am Soc Nephrol 27:2906–2916PubMedPubMedCentral

46.

Dillon MJ, Eleftheriou D, Brogan PA (2010) Medium-size-vessel vasculitis. Pediatr Nephrol 25:1641–1652PubMedCrossRef

47.

Hong Y, Eleftheriou D, Klein NJ, Brogan PA (2015) Impaired function of endothelial progenitor cells in children with primary systemic vasculitis. Arthritis Res Ther 17:292PubMedPubMedCentralCrossRef

48.

Tomasson G, Monach PA, Merkel PA (2009) Thromboembolic disease in vasculitis. Curr Opin Rheumatol 21:41–46PubMedPubMedCentralCrossRef

49.

Brogan PA, Dillon MJ (2004) Endothelial microparticles and the diagnosis of the vasculitides. Intern Med 43:1115–1119PubMedCrossRef

50.

Clarke LA, Shah V, Arrigoni F, Eleftheriou D, Hong Y, Halcox J, Klein N, Brogan PA (2008) Quantitative detection of circulating endothelial cells in vasculitis: comparison of flow cytometry and immunomagnetic bead extraction. J Thromb Haemost 6:1025–1032PubMedCrossRef

51.

Clarke LA, Hong Y, Eleftheriou D, Shah V, Arrigoni F, Klein NJ, Brogan PA (2010) Endothelial injury and repair in systemic vasculitis of the young. Arthritis Rheum 62:1770–1780PubMedCrossRef

52.

Erdbruegger U, Grossheim M, Hertel B, Wyss K, Kirsch T, Woywodt A, Haller H, Haubitz M (2008) Diagnostic role of endothelial microparticles in vasculitis. Rheumatology (Oxford) 47:1820–1825CrossRef

53.

Eleftheriou D, Hong Y, Klein NJ, Brogan PA (2011) Thromboembolic disease in systemic vasculitis is associated with enhanced microparticle-mediated thrombin generation. J Thromb Haemost 9:1864–1867PubMedCrossRef

54.

Eleftheriou D, Ganesan V, Hong Y, Klein NJ, Brogan PA (2012) Endothelial injury in childhood stroke with cerebral arteriopathy: a cross-sectional study. Neurology 79:2089–2096PubMedPubMedCentralCrossRef

55.

Woywodt A, Streiber F, de Groot K, Regelsberger H, Haller H, Haubitz M (2003) Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 361:206–210PubMedCrossRef

56.

Shah V, Christov G, Mukasa T, Brogan KS, Wade A, Eleftheriou D, Levin M, Tulloh RM, Almeida B, Dillon MJ, Marek J, Klein N, Brogan PA (2015) Cardiovascular status after Kawasaki disease in the UK. Heart 101:1646–1655PubMedPubMedCentralCrossRef

57.

Choi JH, Kim KL, Huh W, Kim B, Byun J, Suh W, Sung J, Jeon ES, Oh HY, Kim DK (2004) Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 24:1246–1252PubMedCrossRef

58.

Mohan S, Barsalou J, Bradley TJ, Slorach C, Reynolds JA, Hasni S, Thompson B, Ng L, Levy D, Silverman E, Kaplan MJ (2015) Endothelial progenitor cell phenotype and function are impaired in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol 67:2257–2262PubMedPubMedCentralCrossRef

59.

Dimmeler S, Zeiher AM (2004) Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis? J Mol Med 82:671–677PubMedCrossRef

60.

Sabatier F, Camoin-Jau L, Anfosso F, Sampol J, Dignat-George F (2009) Circulating endothelial cells, microparticles and progenitors: key players towards the definition of vascular competence. J Cell Mol Med 13:454–471PubMedCrossRef

61.

Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967PubMedCrossRef

62.

Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348:593–600PubMedCrossRef

63.

Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M, Nickenig G (2005) Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 353:999–1007PubMedCrossRef

64.

Cheung YF, Brogan PA, Pilla CB, Dillon MJ, Redington AN (2002) Arterial distensibility in children and teenagers: normal evolution and the effect of childhood vasculitis. Arch Dis Child 87:348–351PubMedPubMedCentralCrossRef

65.

Mukhtyar C, Brogan P, Luqmani R (2009) Cardiovascular involvement in primary systemic vasculitis. Best Pract Res Clin Rheumatol 23:419–428PubMedCrossRef

66.

Zavada J, Kideryova L, Pytlik R, Hruskova Z, Tesar V (2009) Reduced number of endothelial progenitor cells is predictive of early relapse in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology (Oxford) 48:1197–1201CrossRef

67.

Eleftheriou D, Ganesan V, Hong Y, Klein NJ, Brogan PA (2015) Endothelial repair in childhood arterial ischaemic stroke with cerebral arteriopathy. Cerebrovasc Dis Extra 5:68–74PubMedPubMedCentralCrossRef

68.

Cellucci T, Tyrrell PN, Pullenayegum E, Benseler SM (2012) Von Willebrand factor antigen—a possible biomarker of disease activity in childhood central nervous system vasculitis? Rheumatology (Oxford) 51:1838–1845CrossRef

69.

Salmela A, Ekstrand A, Joutsi-Korhonen L, Raisanen-Sokolowski A, Lassila R (2015) Activation of endothelium, coagulation and fibrinolysis is enhanced and associates with renal anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant 30[Suppl 1]:i53–i59PubMedCrossRef

70.

Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR (2002) Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 360:1197–1202PubMedCrossRef

71.

Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, Arend WP, Edworthy SM, Fauci AS, Leavitt RY, Lie JT (1990) The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum 33:1114–1121PubMedCrossRef

72.

Amoli MM, Thomson W, Hajeer AH, Calvino MC, Garcia-Porrua C, Ollier WE, Gonzalez-Gay MA (2002) HLA-B35 association with nephritis in Henoch-Schonlein purpura. J Rheumatol 29:948–949PubMed

73.

Amoli MM, Thomson W, Hajeer AH, Calvino MC, Garcia-Porrua C, Ollier WE, Gonzalez-Gay MA (2001) HLA-DRB1*01 association with Henoch-Schonlein purpura in patients from northwest Spain. J Rheumatol 28:1266–1270PubMed

74.

Peru H, Soylemezoglu O, Gonen S, Cetinyurek A, Bakkaloglu SA, Buyan N, Hasanoglu E (2008) HLA class 1 associations in Henoch Schonlein purpura: increased and decreased frequencies. Clin Rheumatol 27:5–10PubMedCrossRef

75.

Amoli MM, Mattey DL, Calvino MC, Garcia-Porrua C, Thomson W, Hajeer AH, Ollier WE, Gonzalez-Gay MA (2001) Polymorphism at codon 469 of the intercellular adhesion molecule-1 locus is associated with protection against severe gastrointestinal complications in Henoch-Schonlein purpura. J Rheumatol 28:1014–1018PubMed

76.

Gershoni-Baruch R, Broza Y, Brik R (2003) Prevalence and significance of mutations in the familial Mediterranean fever gene in Henoch-Schonlein purpura. J Pediatr 143:658–661PubMedCrossRef

77.

Ozcakar ZB, Yalcinkaya F, Cakar N, Acar B, Kasapcopur O, Uguten D, Soy D, Kara N, Uncu N, Arisoy N, Ekim M (2008) MEFV mutations modify the clinical presentation of Henoch-Schonlein purpura. J Rheumatol 35:2427–2429PubMedCrossRef

78.

Eleftheriou D, Brogan PA (2012) The molecular biology and treatment of childhood systemic vasculitis. In: Homeister JW, Willis MS (eds) Molecular and translational vascular medicine, 1st edn. Springer, New York, pp 35–70CrossRef

79.

Al-Sheyyab M, Batieha A, el-Shanti H, Daoud A (1999) Henoch-Schonlein purpura and streptococcal infection: a prospective case–control study. Ann Trop Paediatr 19:253–255PubMedCrossRef

80.

Allen DM, Diamond LK, Howell DA (1960) Anaphylactoid purpura in children (Schonlein-Henoch syndrome): review with a follow-up of the renal complications. AMA J Dis Child 99:833–854PubMedCrossRef

81.

Gairdner D (1948) The Schonlein-Henoch syndrome (anaphylactoid purpura). Q J Med 17:95–122PubMed

82.

Masuda M, Nakanishi K, Yoshizawa N, Iijima K, Yoshikawa N (2003) Group A streptococcal antigen in the glomeruli of children with Henoch-Schonlein nephritis. Am J Kidney Dis 41:366–370PubMedCrossRef

83.

Atkinson SR, Barker DJ (1976) Seasonal distribution of Henoch-Schonlein purpura. Br J Prev Soc Med 30:22–25PubMedPubMedCentral

84.

Levy M, Broyer M, Arsan A, Levy-Bentolila D, Habib R (1976) Anaphylactoid purpura nephritis in childhood: natural history and immunopathology. Adv Nephrol Necker Hosp 6:183–228PubMed

85.

Matsukura H, Ohtsuki A, Fuchizawa T, Miyawaki T (2003) Acute poststreptococcal glomerulonephritis mimicking Henoch-Schonlein purpura. Clin Nephrol 59:64–65PubMedCrossRef

86.

Courtney PA, Patterson RN, Lee RJ (2001) Henoch-Schonlein purpura following meningitis C vaccination. Rheumatology (Oxford) 40:345–346CrossRef

87.

Lambert EM, Liebling A, Glusac E, Antaya RJ (2003) Henoch-Schonlein purpura following a meningococcal vaccine. Pediatrics 112, e491PubMedCrossRef

88.

Eisenstein EM (2002) Lack of evidence for herpesvirus, retrovirus, or parvovirus infection in Henoch-Schonlein purpura. Clin Exp Rheumatol 20:734PubMed

89.

Heegaard ED, Taaning EB (2002) Parvovirus B19 and parvovirus V9 are not associated with Henoch- Schonlein purpura in children. Pediatr Infect Dis J 21:31–34PubMedCrossRef

90.

Minohara Y (1995) Studies on the relationship between anaphylactoid purpura and human parvovirus B19. Kansenshogaku Zasshi 69:928–933PubMedCrossRef

91.

Watanabe T, Oda Y (2000) Henoch-Schonlein purpura nephritis associated with human parvovirus B19 infection. Pediatr Int 42:94–96PubMedCrossRef

92.

Giangiacomo J, Tsai CC (1977) Dermal and glomerular deposition of IgA in anaphylactoid purpura. Am J Dis Child 131:981–983PubMed

93.

Lau KK, Suzuki H, Novak J, Wyatt RJ (2010) Pathogenesis of Henoch-Schonlein purpura nephritis. Pediatr Nephrol 25:19–26PubMedCrossRef

94.

Kiryluk K, Moldoveanu Z, Sanders JT, Eison TM, Suzuki H, Julian BA, Novak J, Gharavi AG, Wyatt RJ (2011) Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schonlein purpura nephritis. Kidney Int 80:79–87PubMedPubMedCentralCrossRef

95.

Boyd JK, Barratt J (2011) Inherited IgA glycosylation pattern in IgA nephropathy and HSP nephritis: where do we go next? Kidney Int 80:8–10PubMedCrossRef

96.

Brendel-Muller K, Hahn A, Schneppenheim R, Santer R (2001) Laboratory signs of activated coagulation are common in Henoch- Schonlein purpura. Pediatr Nephrol 16:1084–1088PubMedCrossRef

97.

Gunasekaran TS, Berman J, Gonzalez M (2000) Duodenojejunitis: is it idiopathic or is it Henoch-Schonlein purpura without the purpura? J Pediatr Gastroenterol Nutr 30:22–28PubMedCrossRef

98.

Kamitsuji H, Tani K, Yasui M, Taniguchi A, Taira K, Tsukada S, Iida Y, Kanki H, Fukui H (1987) Activity of blood coagulation factor XIII as a prognostic indicator in patients with Henoch-Schonlein purpura. Efficacy of factor XIII substitution. Eur J Pediatr 146:519–523PubMedCrossRef

99.

Kawasaki K, Komura H, Nakahara Y, Shiraishi M, Higashida M, Ouchi K (2006) Factor XIII in Henoch-Schonlein purpura with isolated gastrointestinal symptoms. Pediatr Int 48:413–415PubMedCrossRef

100.

Makay B, Gucenmez OA, Duman M, Unsal E (2014) The relationship of neutrophil-to-lymphocyte ratio with gastrointestinal bleeding in Henoch-Schonlein purpura. Rheumatol Int 34:1323–1327PubMedCrossRef

101.

Ozturk K, Ekinci Z (2016) Is neutrophil-to-lymphocyte ratio valid to predict organ involvement in Henoch-Schonlein purpura? Rheumatol Int 36:1147–1148PubMedCrossRef

102.

Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, Stone DL, Chae JJ, Rosenzweig SD, Bishop K (2014) Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med 370:911–920PubMedPubMedCentralCrossRef

103.

Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, Zlotogorski A, Berkun Y, Press JJ, Mukamel M (2014) Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med 370:921–931PubMedCrossRef

104.

Liu Y, Jesus AA, Marrero B, Yang D, Ramsey SE, Montealegre Sanchez GA, Tenbrock K, Wittkowski H, Jones OY, Kuehn HS (2014) Activated STING in a vascular and pulmonary syndrome. N Engl J Med 371:507–518PubMedPubMedCentralCrossRef

105.

Liu Y, Ramot Y, Torrelo A, Paller AS, Si N, Babay S, Kim PW, Sheikh A, Lee CCR, Chen Y (2012) Mutations in PSMB8 cause CANDLE syndrome with evidence of genetic and phenotypic heterogeneity. Arthritis Rheum 64:895PubMedPubMedCentralCrossRef

106.

Batu ED, Karadag O, Taskiran EZ, Kalyoncu U, Aksentijevich I, Alikasifoglu M, S Ö (2015) A case series of adenosine deaminase 2-deficient patients emphasizing treatment and genotype-phenotype correlations. J Rheumatol 42:1532–1534PubMedCrossRef

107.

Nanthapisal S, Murphy C, Omoyinmi E, Standing A, Hong Y, Gomes SM, Klein N, Eleftheriou D, Brogan PA (2015) Monogenic polyarteritis nodosa caused by ADA2 deficiency: the GOSH experience. Pediatr Rheumatol 13:8CrossRef

108.

Van Montfrans J, Zavialov A, Zhou Q, Zhou Q, Yang D, Ombrello AK (2014) Mutant ADA2 in vasculopathies. N Engl J Med 2014:478–481

109.

Nanthapisal S, Murphy C, Omoyinmi E, Hong Y, Standing A, Berg S, Ekelund M, Jolles S, Harper L, Youngstein T, Gilmour K, Klein NJ, Eleftheriou D, Brogan PA (2016) Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheumatol 68:2314–2322PubMedCrossRef

110.

Brehm A, Liu Y, Sheikh A, Marrero B, Omoyinmi E, Zhou Q, Montealegre G, Biancotto A, Reinhardt A, de Jesus AA (2015) Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J Clin Invest 125:4196–4211PubMedPubMedCentralCrossRef

111.

Omoyinmi E, Melo Gomes S, Nanthapisal S, Woo P, Standing A, Eleftheriou D, Klein N, Brogan PA (2015) Stimulator of interferon genes-associated vasculitis of infancy. Arthritis Rheumatol 67:808PubMedCrossRef

112.

Crow YJ (2011) Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci 1238:91–98PubMedCrossRef

113.

Volpi S, Picco P, Caorsi R, Candotti F, Gattorno M (2016) Type I interferonopathies in pediatric rheumatology. Pediatr Rheumatol 14:35CrossRef

114.

Dolezalova P, Price-Kuehne FE, Ozen S, Benseler SM, Cabral DA, Anton J, Brunner J, Cimaz R, O’Neil KM, Wallace CA, Wilkinson N, Eleftheriou D, Demirkaya E, Bohm M, Krol P, Luqmani RA, Brogan PA (2013) Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score (PVAS). Ann Rheum Dis 72:1628–1633PubMedCrossRef

Medicine Matters Rheumatology

Abstract